Skip to main
MIRM

MIRM Stock Forecast & Price Target

MIRM Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mirum Pharmaceuticals has demonstrated substantial growth, primarily driven by strong sales of its product LIVMARLI, which recorded $88.1 million in revenue during 2Q25, reflecting an impressive 87% year-over-year increase. The company has increased its 2025 revenue guidance to a range of $490 million to $510 million, up from a previous estimate of $435 million to $450 million, indicating robust commercial momentum and positive market response. Furthermore, the total revenues for 2Q25 reached $127.8 million, a 64% year-over-year increase, showcasing the company’s strong performance and higher-than-expected adoption rates for its therapies.

Bears say

Mirum Pharmaceuticals faces significant commercial risk due to its dependence on non-composition of matter patent coverage for maralixibat, which may hinder its competitive position in a crowded market of ASBT inhibitors. The company’s revenue remains in an early growth phase, and potential competition or slower sales growth may impede its path to profitability. Additionally, the recent loss from the termination of a revenue interest purchase agreement highlights financial vulnerabilities, and the inherent volatility of biotech stocks amplifies the downside risk associated with clinical trial outcomes and market dynamics.

MIRM has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast

Analysts have given MIRM a Buy based on their latest research and market trends.

According to 12 analysts, MIRM has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirum Pharmaceuticals Inc (MIRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.